LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Listă Acțiuni・Compugen Ltd

Compugen Ltd

Închisă

2.03 -2.87

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

2.12

Indicatori cheie
By Trading Economics
Venit	-65M -7.7M
Vânzări	-65M 2.2M
P/E Medie Sector	6.474 49.888
EPS	-0.08
Marjă de profit	-352.436
Angajați	75
EBITDA	-64M -7.7M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+138.1% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-38M 233M
Deschiderea anterioară	4.9
Închiderea anterioară	2.03

Compugen Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 iun. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 iun. 2026, 15:41 UTC

Principalele dinamici ale pieței

American Battery Shares Jump on Energy Department Victory

8 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 iun. 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 21:57 UTC

Achiziții, Fuziuni, Preluări

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 iun. 2026, 21:56 UTC

Achiziții, Fuziuni, Preluări

Salesforce Agrees to Buy m3ter

8 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 iun. 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 iun. 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 iun. 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 iun. 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 iun. 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 iun. 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 iun. 2026, 16:55 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 iun. 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 iun. 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 iun. 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 iun. 2026, 16:03 UTC

Achiziții, Fuziuni, Preluări

Orange Bought Stake From Lorca

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 iun. 2026, 16:01 UTC

Achiziții, Fuziuni, Preluări

Orange Acquires 100% Ownership of MasOrange

8 iun. 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 iun. 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 iun. 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 iun. 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparație

Modificare preț

Compugen Ltd Așteptări

Obiectiv de preț

By TipRanks

138.1% sus

Prognoză pe 12 luni

Medie 5 USD 138.1%

Maxim 6 USD

Minim 4 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCompugen Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 3 analiști care au acordat evaluări ale acțiunilor Compugen Ltd - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.